NCT05066373View on ClinicalTrials.gov

Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

August 11, 2022

Study Completion Date

August 26, 2022

Conditions
DisintegrationHealthy
Interventions
DRUG

EDP1815 capsule A

EDP1815 capsule A is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA

DRUG

EDP1815 capsule B

EDP1815 capsule B is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA

DRUG

EDP1815 tablet

EDP1815 tablet is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The tablet is radio-labeled with approximately 4 MBq 99mTc-DTPA

Trial Locations (1)

G4 0SF

BDD Pharma Ltd, Glasgow

Sponsors
All Listed Sponsors
lead

Evelo Biosciences, Inc.

INDUSTRY

NCT05066373 - Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms | Biotech Hunter | Biotech Hunter